Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff Oncology (NAS:CRDF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Cardiff Oncology Forward PE Ratio Related Terms
Cardiff Oncology Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology Forward PE Ratio Chart
Cardiff Oncology Annual Data
Trend
Forward PE Ratio
Cardiff Oncology Quarterly Data
Forward PE Ratio
CRDF vs MAIA, TELO, OSTX: Forward PE Ratio Comparison
For the Biotechnology subindustry, Cardiff Oncology's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Cardiff Oncology (CRDF) has a Forward PE Ratio of 0.00 as of Jul. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Cardiff Oncology and its competitors. According to the industry distribution chart, Cardiff Oncology ranks #999999 out of 354 companies in the Biotechnology industry.
Is Cardiff Oncology's Forward PE Ratio too high?
Cardiff Oncology's current Forward PE Ratio is 0.00. Based on the distribution chart, Cardiff Oncology ranks #999999 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cardiff Oncology has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Forward PE Ratio compare to MAIA and TELO?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #999999 out of 354 companies for Forward PE Ratio. This places Cardiff Oncology in the lower half of its industry. The industry median Forward PE Ratio is 21.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.97, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Cardiff Oncology and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.40, compared to a current price of $0.88 — trading 37.1% below its estimated fair value. The current Forward PE Ratio is 0.00. Cardiff Oncology's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Forward PE Ratio is 0.00 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Oncology (CRDF) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued.
The current stock price of $0.88 is trading 37.1% below its estimated GF Value™ of $1.40.
GuruFocus considers Cardiff Oncology to be Possible Value Trap.
Key valuation signals for CRDF:
Forward PE Ratio: 0.00
GF Value™: $1.40 vs. price of $0.88 (37.1% below fair value)
No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
44GF Score
Get the complete analysis for CRDF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
